Safety, Tolerability and Efficacy of PfSPZ Vaccine Administered by Direct Venous Inoculation (DVI) to Healthy Children and Infants 5 Months Through 9 Years of Age Living in an Area of High Malaria Transmission in Western Kenya: Age De-escalation and Dose Escalation and a Double Blind, Randomized Placebo-Controlled Trial for Safety and Efficacy
Latest Information Update: 14 Dec 2021
At a glance
- Drugs Malaria vaccine live attenuated-Sanaria (Primary)
- Indications Falciparum malaria
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Sanaria
- 01 Sep 2021 Results assessing safety, immunogenicity and vaccine efficacy after DVI of PfSPZ Vaccine in 5-12-month-old infants in Kenya, published in the Nature Medicine.
- 19 May 2020 Results published in the Vaccine
- 26 Sep 2019 Results assessing safety, tolerability and immunogenicity of various dose regimens of PfSPZ Vaccine published in the Clinical Infectious Diseases